Nivolumab (OpdivoR), a fully human IgG4 anti-PD-1 mAb which interrupts PD-1 activation, leading to an enhanced immune response against tumor cells, was approved in 2016 for the treatment of relapsed or refractory HL [199]. Here, PDCD1 is linked to neoplasm.